1 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
2 | 90 mg hydrocortisone acetate suppository with Sephure suppository applicator (Acticort (TN)) | 3件: Acetate Acetate, Hydrocortisone, Hydrocortisone acetate (Actinac Pws) | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Hydrocortisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
3 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as | - | - | - | - | 1件: 254 254 💬 |
4 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R) | - | - | - | - | 1件: 51 51 💬 |
5 | Abatacept Active Treatment | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 💬 |
6 | Abatacept, rituximab or tocilizumab (Actemra (TN)) | 3件: Abatacept Abatacept, Rituximab, Tocilizumab (Actemra ACTPen) | 3件: Tocilizumab
Tocilizumab
(Actemra (TN)),
Rituximab
,
Abatacept
💬 | 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
7 | ACT | - | - | - | - | 1件: 13 13 💬 |
8 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
9 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
10 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
11 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
12 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
13 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
14 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
15 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
16 | ACT-1 | - | - | - | - | 1件: 13 13 💬 |
17 | ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
18 | ACT-128800 Dose 1 | - | - | - | - | 1件: 13 13 💬 |
19 | ACT-128800 Dose 2 | - | - | - | - | 1件: 13 13 💬 |
20 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
21 | ACT-178418 | - | - | - | - | 1件: 86 86 💬 |
22 | ACT-293987 | - | - | - | - | 3件: 51 51, 86, 88 💬 |
23 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
24 | ACT-293987 / JNJ-67896049 | - | - | - | - | 1件: 84 84 💬 |
25 | ACT-334441 | - | - | - | - | 1件: 49 49 💬 |
26 | ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
27 | ACT-385781A (Actelion Epoprostenol) | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
28 | ACT-434964 | - | - | - | - | 1件: 19 19 💬 |
29 | Act-HiB | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB) | - | - | - | 4件: 14 14, 61, 62, 222 💬 |
30 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB) | - | - | - | 2件: 61 61, 62 💬 |
31 | Actemra | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
32 | Actemra(EU-licensed) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
33 | Actemra, MRA | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 💬 |
34 | Acteoside | 1件: Acteoside Acteoside | - | - | - | 1件: 66 66 💬 |
35 | ACTH | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 4件: 13 13, 66, 145, 222 💬 |
36 | ACTH (Acthar) Gel | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 66 66 💬 |
37 | Acthar | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 9件: 2 2, 13, 14, 46, 49, 50, 66, 84, 222 💬 |
38 | Acthar 80 unit injection | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 66 66 💬 |
39 | Acthar Gel | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 6件: 13 13, 46, 49, 50, 84, 222 💬 |
40 | ACTHAR Gel (ACTH) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
41 | ACTHAR Gel (adrenocorticotropic hormone) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
42 | ACTHAR Gel 40 units twice weekly | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
43 | ACTHAR Gel 80 units twice weekly. | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
44 | Acthar high dose (80 U) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
45 | Acthar Injectable Product | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 46 46 💬 |
46 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
47 | ActHIB | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB) | - | - | - | 2件: 62 62, 66 💬 |
48 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB) | - | - | - | 2件: 62 62, 66 💬 |
49 | Acthrel | 1件: Corticorelin ovine triflutate Corticorelin ovine triflutate (Acthrel) | 1件: Corticorelin ovine triflutate
Corticorelin ovine triflutate
(Acthrel (TN)) 💬 | 2件: CRHR1 CRHR1, CRHR2 💬 | 4件: Cushing syndrome Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
50 | ACTIMMUNE | 1件: Interferon gamma-1b Interferon gamma-1b (Actimmune) | 1件: Interferon gamma-1b
Interferon gamma-1b
(Actimmune (TN)) 💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 1件: 326 326 💬 |
51 | Actimmune Registry | 1件: Interferon gamma-1b Interferon gamma-1b (Actimmune) | 1件: Interferon gamma-1b
Interferon gamma-1b
(Actimmune (TN)) 💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 1件: 326 326 💬 |
52 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. | - | - | - | - | 1件: 276 276 💬 |
53 | Active comparator | - | - | - | - | 2件: 6 6, 46 💬 |
54 | Active Comparator receiving Extavia® | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
55 | Active Control | - | - | - | - | 1件: 13 13 💬 |
56 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
57 | Active drug: pimavanserin 17mg (2 strength tablets) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
58 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
59 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
60 | Active Treatment Group 7% Hypertonic Saline | - | - | - | - | 1件: 299 299 💬 |
61 | ActiveMatrix | - | - | - | - | 1件: 70 70 💬 |
62 | Actonel 5mg Film Coated Tablets | 1件: Risedronic acid Risedronic acid (Actonel Plus Calcium) | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
63 | Actonel Once a Week 35 mg film-coated tablets | 1件: Risedronic acid Risedronic acid (Actonel Plus Calcium) | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
64 | Actonel Once a week 5mg film coated tablets | 1件: Risedronic acid Risedronic acid (Actonel Plus Calcium) | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 113 113 💬 |
65 | Actonel/Optinate 5mg film-coated tablets | 1件: Risedronic acid Risedronic acid (Actonel Plus Calcium) | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
66 | ACTOS (Pioglitazone) | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 13 13 💬 |
67 | Actos 15 mg | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
68 | Actos 30 mg | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
69 | Actos 45 mg | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
70 | Actrapid 100 IU/ml, Solution for injection in a vial | - | - | - | - | 1件: 299 299 💬 |
71 | Actrapid Penfill 100UI/ml | - | - | - | - | 1件: 299 299 💬 |
72 | ActRIIA-IgG1Fc | - | - | - | - | 1件: 86 86 💬 |
73 | ACTUS-101 | - | - | - | - | 1件: 256 256 💬 |
74 | Adalimuab, Etanercept, Tocilizumab, or Abatacept (Actemra (TN)) | 3件: Abatacept Abatacept, Etanercept, Tocilizumab (Actemra ACTPen) | 3件: Etanercept
Etanercept
,
Tocilizumab
(Actemra (TN)),
Abatacept
💬 | 5件: CD80 CD80, CD86, IL6R, LTA, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
75 | Adjuvant without active component | - | - | - | - | 2件: 6 6, 17 💬 |
76 | Adrenocorticotrophic hormone ACTH | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 222 222 💬 |
77 | Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
78 | Anti BAFF (B cell activating factor) | - | - | - | - | 1件: 49 49 💬 |
79 | Anxiety/depression and work and activities | - | - | - | - | 1件: 13 13 💬 |
80 | Biologically active human fecal microbiota | - | - | - | - | 1件: 97 97 💬 |
81 | BT-11 Active | - | - | - | - | 2件: 96 96, 97 💬 |
82 | CFZ533 active - Cohort 1 | - | - | - | - | 1件: 53 53 💬 |
83 | CFZ533 active - Cohort 2 | - | - | - | - | 1件: 53 53 💬 |
84 | CFZ533 active - Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
85 | CFZ533 active -Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
86 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
87 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
88 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
89 | Combination Oral Budesonide and Rectal Hydrocortisone (Acticort (TN)) | 2件: Budesonide Budesonide, Hydrocortisone | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
90 | Combination Product: Active treatment with dual therapy | - | - | - | - | 1件: 2 2 💬 |
91 | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) (Acticort (TN)) | 7件: Acetate Acetate, Cortisone, Cortisone acetate, Dexamethasone, Hydrocortisone, Prednisolone, Prednisone | 6件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Dexamethasone
,
Prednisolone
,
Prednisone
,
Cortisone acetate
,
Cortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
92 | Cortef (hydrocortisone) (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
93 | Corticoids+ tocilizumab 8mg/Kg/4 weeks (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
94 | Corticotropin (ACTH (TN)) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 7件: 2 2, 13, 46, 75, 81, 84, 222 💬 |
95 | Corticotropin-releasing hormone (ACTH (TN)) | 2件: Corticorelin Corticorelin, Corticotropin (Acthar) | 2件: Corticotropin
Corticotropin
(ACTH (TN)),
Corticorelin
💬 | 3件: CRHR1 CRHR1, CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
96 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. (ACTH (TN)) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 💬 |
97 | CT-P47 AI (tocilizumab) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
98 | CT-P47 PFS (tocilizumab) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
99 | Decrease Tocilizumab, Abatacept (Actemra (TN)) | 2件: Abatacept Abatacept, Tocilizumab (Actemra ACTPen) | 2件: Tocilizumab
Tocilizumab
(Actemra (TN)),
Abatacept
💬 | 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
100 | Dual release hydrocortisone (plenadren) (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
101 | EFI/ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
102 | Epoprostenol-Actelion | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
103 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab (Actemra (TN)) | 4件: Abatacept Abatacept, Rituximab, Sarilumab, Tocilizumab (Actemra ACTPen) | 4件: Tocilizumab
Tocilizumab
(Actemra (TN)),
Rituximab
,
Abatacept
,
Sarilumab
💬 | 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
104 | Fenofibrate Combined With Ursodeoxycholic Acid (Actigall (TN)) | 2件: Fenofibrate Fenofibrate, Ursodeoxycholic acid (Actigall) | 2件: Fenofibrate
Fenofibrate
,
Ursodiol
(Actigall (TN)) 💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
105 | Gene Activated a-Galactosidase A | - | - | - | - | 1件: 19 19 💬 |
106 | Gene Activated Human Glucocerebrosidase | - | - | - | - | 1件: 19 19 💬 |
107 | Gene activated human glucocerebrosidase, velaglucerase alfa | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
108 | Gene-Activated Human Glucocerebrosidase | - | - | - | - | 1件: 19 19 💬 |
109 | Gene-Activated Human Glucocerebrosidase 200U/vial | - | - | - | - | 1件: 19 19 💬 |
110 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 💬 |
111 | H.P. Acthar Gel | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 5件: 46 46, 49, 50, 84, 222 💬 |
112 | H.P. Acthar Gel (repository corticotropin injection) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
113 | H.P. Acthar® Gel | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 14 14 💬 |
114 | HrIL-2 active | - | - | - | - | 3件: 46 46, 49, 53 💬 |
115 | Hydrocortisone (Acticort (TN)) | 2件: Hydrocortisone Hydrocortisone, Hydrocortisone acetate (Actinac Pws) | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Hydrocortisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 10件: 6 6, 41, 46, 53, 75, 78, 81, 83, 97, 299 💬 |
116 | Hydrocortisone (Solucortef) (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
117 | Hydrocortisone 100mg/ml (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
118 | Hydrocortisone 10mg (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
119 | Hydrocortisone 10mg Tablet (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
120 | Hydrocortisone 10mg Tablets (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
121 | Hydrocortisone 20mg Tablets (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
122 | HYDROCORTISONE ACETATE (Acticort (TN)) | 3件: Acetate Acetate, Hydrocortisone, Hydrocortisone acetate (Actinac Pws) | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Hydrocortisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
123 | Hydrocortisone cream (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
124 | Hydrocortisone cream 1% (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
125 | Hydrocortisone cream 10mg/g FNA Fagron (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
126 | HYDROCORTISONE HYDROGEN SUCCINATE (Acticort (TN)) | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone succinate, Hydrogen | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
127 | HYDROCORTISONE MICRONIZED (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
128 | Hydrocortisone Modified Release Capsules (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
129 | HYDROCORTISONE ROUSSEL (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
130 | Hydrocortisone sodium acetate (Acticort (TN)) | 3件: Acetate Acetate, Hydrocortisone, Sodium acetate | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Sodium acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
131 | HYDROCORTISONE SODIUM PHOSPHATE (Acticort (TN)) | 2件: Hydrocortisone Hydrocortisone, Phosphate ion | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 53 53, 81, 83 💬 |
132 | HYDROCORTISONE SODIUM SUCCINATE (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 81 81, 83, 97 💬 |
133 | Hydrocortisone tablet 2.5 mg (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
134 | Hydrocortisone TAKEDA, tabletter (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
135 | HYDROCORTISONE- hydrocortisone tablet (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
136 | INN-Tocilizumab (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 💬 |
137 | INTERFERON GAMMA-1B (Actimmune (TN)) | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b (Actimmune) | 1件: Interferon gamma-1b
Interferon gamma-1b
(Actimmune (TN)) 💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 7件: 18 18, 65, 85, 228, 299, 301, 326 💬 |
138 | Interferon gamma-1b (Actimmune) | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b (Actimmune) | 1件: Interferon gamma-1b
Interferon gamma-1b
(Actimmune (TN)) 💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 1件: 85 85 💬 |
139 | Intra-articular Tocilizumab (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
140 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 💬 |
141 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
142 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
143 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
144 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
145 | Lamotrigin actavis | - | - | - | - | 1件: 114 114 💬 |
146 | Long-Acting Growth Hormone (LAGH) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
147 | Long-acting somatostatin | 1件: Somatostatin Somatostatin | 1件: Somatostatin
Somatostatin
💬 | 5件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 67 67 💬 |
148 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
149 | Mesalazine with hydrocortisone sodium succinate (Acticort (TN)) | 2件: Hydrocortisone Hydrocortisone, Mesalazine | 2件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Mesalamine
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
150 | MRA (Actemra) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 💬 |
151 | MRA (tocilizumab) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
152 | MRA(Tocilizumab) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
153 | MRA, Actemra | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
154 | Novorapid / humalog short acting insulin | - | - | - | - | 1件: 299 299 💬 |
155 | Octreotide LAR / Sandostatin LAR (LAR=long acting release) | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
156 | Ovine Corticotropin-Releasing Hormone (oCRH) (ACTH (TN)) | 2件: Corticorelin Corticorelin, Corticotropin (Acthar) | 2件: Corticotropin
Corticotropin
(ACTH (TN)),
Corticorelin
💬 | 3件: CRHR1 CRHR1, CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
157 | Pioglitazone (Actos (TN)) | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
158 | Pioglitazone 15 mg (Actos (TN)) | 1件: Pioglitazone Pioglitazone (Actoplus Met) | 1件: Pioglitazone
Pioglitazone
(Actos (TN)) 💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 96 96 💬 |
159 | Pioglitazone and Tretinoin (Actos (TN)) | 2件: Pioglitazone Pioglitazone (Actoplus Met), Tretinoin | 2件: Tretinoin
Tretinoin
,
Pioglitazone
(Actos (TN)) 💬 | 4件: PML PML, PPARG, RARA, RARB 💬 | 21件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 2 2 💬 |
160 | Pioglitazone or metformin (Actos (TN)) | 2件: Metformin Metformin (Actoplus Met), Pioglitazone (Actoplus Met) | 2件: Metformin
Metformin
,
Pioglitazone
(Actos (TN)) 💬 | 3件: PPARG PPARG, PRKAA1, PRKAA2 💬 | 27件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Huntington disease, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Osteoclast differentiation, Oxytocin signaling pathway, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Tight junction, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 265 265 💬 |
161 | Reh-acteoside | 1件: Acteoside Acteoside | - | - | - | 1件: 66 66 💬 |
162 | Repository Corticotropin Injection (ACTH (TN)) | 1件: Corticotropin Corticotropin (Acthar) | 1件: Corticotropin
Corticotropin
(ACTH (TN)) 💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 5件: 2 2, 13, 46, 84, 222 💬 |
163 | Risedronate sodium (Actonel) | 1件: Risedronic acid Risedronic acid (Actonel Plus Calcium) | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
164 | Rituximab, observational study amon patients with active RA | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
165 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
166 | Ro Actemra | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
167 | Ro-Actemra | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
168 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
169 | RoActemra/Actemra (tocilizumab) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 💬 |
170 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
171 | Short-acting Insulin (Actrapid) | - | - | - | - | 1件: 299 299 💬 |
172 | Solu-Cortef (hydrocortisone) (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
173 | Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
(Acticort (TN)),
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
174 | Subcutaneous hydrocortisone 10mg (Acticort (TN)) | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
(Acticort (TN)) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
175 | Subcutaneous tocilizumab (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
176 | Subcutaneous tocilizumab 162mg/biweekly (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
177 | Time and attention + active fructooligosaccharide supplementation | - | - | - | - | 1件: 96 96 💬 |
178 | TOCILIZUMAB (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
179 | Tocilizumab (Actemra or RoActemra) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
180 | Tocilizumab (Actemra) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
181 | Tocilizumab (Actemra®) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
182 | Tocilizumab (MRA-SC) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 40 40 💬 |
183 | Tocilizumab (TCZ) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 56 💬 |
184 | Tocilizumab + Glucocorticoids (GCs) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
185 | Tocilizumab + methotrexate(MTX) (Actemra (TN)) | 2件: Methotrexate Methotrexate, Tocilizumab (Actemra ACTPen) | 2件: Methotrexate
Methotrexate
,
Tocilizumab
(Actemra (TN)) 💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
186 | Tocilizumab 162 mg (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
187 | Tocilizumab 162Mg/0.9Ml Autoinjector (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
188 | Tocilizumab 162mg/0.9ml jeringa SC (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
189 | Tocilizumab 162mg/0.9ml SC PFS SC (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
190 | Tocilizumab 162mg/0.9ml syringe SC (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
191 | Tocilizumab [RoActemra/Actemra] | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 46 46, 51, 107, 331 💬 |
192 | Tocilizumab [RoActemra] (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
193 | Tocilizumab and IV steroids combination (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
194 | Tocilizumab Infusion RoAcemtra (EU) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 💬 |
195 | Tocilizumab Injectable Product (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 11 11 💬 |
196 | Tocilizumab Injection (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
197 | Tocilizumab Injection 8mg/kg (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
198 | Tocilizumab IV (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
199 | Tocilizumab plus methotrexate (Actemra (TN)) | 2件: Methotrexate Methotrexate, Tocilizumab (Actemra ACTPen) | 2件: Methotrexate
Methotrexate
,
Tocilizumab
(Actemra (TN)) 💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
200 | Tocilizumab Prefilled Syringe (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 41 41, 46 💬 |
201 | Tocilizumab Roche (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
202 | TOCILIZUMAB SC (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 41 41, 46, 107 💬 |
203 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
204 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
205 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
206 | Tocilizumab treatment (Actemra (TN)) | 1件: Tocilizumab Tocilizumab (Actemra ACTPen) | 1件: Tocilizumab
Tocilizumab
(Actemra (TN)) 💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
207 | Tocilizumab+Methotrexate(MTX) (Actemra (TN)) | 2件: Methotrexate Methotrexate, Tocilizumab (Actemra ACTPen) | 2件: Methotrexate
Methotrexate
,
Tocilizumab
(Actemra (TN)) 💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
208 | Tocilizumab, Abatacept (Actemra (TN)) | 2件: Abatacept Abatacept, Tocilizumab (Actemra ACTPen) | 2件: Tocilizumab
Tocilizumab
(Actemra (TN)),
Abatacept
💬 | 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
209 | Treatment defined only by active substance | - | - | - | - | 1件: 50 50 💬 |
210 | Tretinoin and Pioglitazone HCL (Actos (TN)) | 2件: Pioglitazone Pioglitazone (Actoplus Met), Tretinoin | 2件: Tretinoin
Tretinoin
,
Pioglitazone
(Actos (TN)) 💬 | 4件: PML PML, PPARG, RARA, RARB 💬 | 21件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 2 2 💬 |
211 | UDCA (Ursodeoxycholic acid) (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
212 | Ursodeoxycholic acid (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 10件: 6 6, 46, 67, 84, 93, 94, 95, 96, 97, 296 💬 |
213 | Ursodeoxycholic acid (UDCA) (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 94 94 💬 |
214 | Ursodeoxycholic acid (UDCA) 500 mg (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 46 46 💬 |
215 | Ursodeoxycholic Acid (URSO) (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
216 | Ursodeoxycholic Acid 300mg capsule (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
217 | Ursodeoxycholic Acid 300mg tablet (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
218 | Ursodeoxycholic Acid Capsules (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
219 | Ursodeoxycholic acid combination of immunosuppressive agents (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 2件: 93 93, 95 💬 |
220 | Ursodeoxycholic acid combined with total glucosides of paeony (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
221 | Ursodeoxycholic acid only (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
222 | Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone) (Actigall (TN)) | 2件: Methylprednisolone Methylprednisolone, Ursodeoxycholic acid (Actigall) | 2件: Methylprednisolone
Methylprednisolone
,
Ursodiol
(Actigall (TN)) 💬 | 2件: NR1H4 NR1H4, NR3C1 💬 | 2件: Bile secretion Bile secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 93 93 💬 |
223 | Ursodiol (ursodeoxycholic acid, UDCA) (Actigall (TN)) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Actigall) | 1件: Ursodiol
Ursodiol
(Actigall (TN)) 💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 97 97 💬 |
224 | UTTR1147A/RO7021610 (Active) | - | - | - | - | 2件: 96 96, 97 💬 |